In patients with CKD, muscle wasting is common and is associated with morbidity and mortality. Mechanisms leading to loss of muscle proteins include insulin resistance, which suppresses Akt activity and thus stimulates protein degradation via the ubiquitin-proteasome system. However, the specific factors controlling CKD-induced suppression of Akt activity in muscle remain undefined. In mice with CKD, the reduction in Akt activity in muscle exceeded the decrease in upstream insulin receptor substrate-1-associated phosphatidylinositol 3-kinase activity, suggesting that CKD activates other pathways that suppress Akt. Furthermore, a CKD-induced increase uncovered caspase-3 activity in muscle in these mice. In C2C12 muscle cells, activated caspase-3 cleaves and activates Rho-associated protein kinase 1 (ROCK1), which enhances the activity of phosphatase and tensin homolog (PTEN) and reduces Akt activity. Notably, constitutive activation of ROCK1 also led to increased caspase-3 activity in vitro. In mice with either global ROCK1 knockout or muscle-specific PTEN knockout, CKD-associated muscle proteolysis was blunted. These results suggest ROCK1 activation in CKD and perhaps in other catabolic conditions can promote loss of muscle protein via a negative feedback loop.
myofibrillar proteins producing substrates that are degraded in the UPS. Second, activated caspase-3 cleaves specific subunits of the 19S proteasome particle, and this in turn stimulates proteolysis in the 26S proteasome. When caspase-3 is inhibited by overexpression of XIAP in muscle, muscle wasting is suppressed in mouse models of CKD. Caspase-3 also affects signal transduction because caspase-3 activation in Jurkat T cells stimulates apoptosis through an interaction between caspase-3 and Rhoassociated kinase 1 (ROCK1). The interaction involves cleavage of an inhibitory Cys domain at the Cterminus of ROCK1, producing an increase in ROCK1 activity.
Activated ROCK1 reportedly stimulates cell migration, autophagy, differentiation, and apoptosis in different types of cells or tissues.
In cultured embryonic kidney cells, activated ROCK1 phosphorylates phosphatase and tensin homolog (PTEN) creating phosphatase activity.
The action of PTEN reduces the level of phosphatidylinositol (3,4,5)-trisphosphate and impairs Akt activity. This is relevant to CKD-induced muscle protein losses because we have found that activated PTEN stimulates muscle proteolysis in the UPS.
We examined the kinase activity of Akt in a mouse model of CKD and found it was unexpectedly lower than the kinase activity of phosphatidylinositol 3-kinase (PI3K). We also uncovered a new, CKD-induced pathway that stimulates muscle protein wasting via activation of caspase-3, which stimulates ROCK1 kinase activity. ROCK1 in turn stimulates PTEN activity, which suppresses the kinase activity of Akt and stimulates muscle protein degradation. Our results provide a new mechanism contributing to the CKDinduced muscle protein degradation and suggest therapeutic targets for blocking the muscle wasting.
Results

ROCK1 Is Activated in Skeletal Muscles of Mice with CKD
Mammalian ROCK1 can be activated by either a small GTPase, which binds the Rho domain, or by removal of the inhibitory Cys domain. In the latter case, caspase-3 recognizes and cleaves the DETDconserved consensus sequence at amino acid position 1113 of ROCK1 ( Figure 1A ). When ROCK1 is activated in epithelial or endothelial cells by proteolytic cleavage, the cells undergo apoptosis and death. In skeletal muscle of normal mice, we found abundant expression of ROCK1 ( Figure 1B ). In skeletal muscles of mice with CKD, there was an expression of the intact ROCK1 protein (160 kD) plus an increase in the cleaved 130-kD fragment of activated ROCK1 ( Figure 1C ). To assess the physiologic relevance of ROCK1 cleavage, we measured ROCK1 activity in muscles using the MYPT1 substrate. Notably, there was a 2.6-fold increase in ROCK1 activity (P<0.05) in muscles of CKD mice versus results from muscles of control mice ( Figure 1D ). Because RhoA GTPase is an upstream activator of ROCK1, we also measured RhoA activity; there was no evidence of increased RhoA activity ( Figure 1E ). We conclude that ROCK1 is activated in muscles of CKD mice principally by cleavage of ROCK1.
CKD Stimulates Caspase-3 in Skeletal Muscle To Activate ROCK1
Previously, we uncovered that CKD activates caspase-3 in muscles of rats leading to a significant increase in the 19-kD, active fragment of caspase-3.
In these experiments, the 19-kD active fragment of caspase-3 was present in muscles of mice with CKD ( Figure 2A ). The presence of caspase-3 activity was confirmed by immunofluorescent staining of active caspase-3 in myofibers of muscles in mice with CKD ( Figure 2B ). These results demonstrate that active caspase-3 is located only in the cytoplasm and not in the nuclei of myofibers indicating that activated caspase-3 does not stimulate apoptosis. The absence of apoptosis was verified by negative results of a terminal deoxynucleotidyl transferase-mediated digoxigenin-deoxyuridine nick-end labeling (TUNEL) assay in myofibers ( Figure 2 , C and D).
To determine if caspase-3 is activated in muscles of patients with CKD, we examined western blots of samples of abdominal muscles obtained from CKD and healthy individuals of similar ages and sexes. Activated caspase-3 was detected in muscles from patients with CKD versus control subjects ( Figure 2E ). Immunofluorescence microscopy confirmed that active caspase-3 was mainly located in myofibers ( Figure 2F ). Therefore, both in rodent models of CKD and in patients with CKD, caspase-3 is activated in skeletal muscles.
To ascertain if there is linkage between activated caspase-3 and ROCK1 activity, we examined C2C12 myoblasts. First, we activated caspase-3 in C2C12 myoblasts by transfecting them with a plasmid that expresses inducible activity of caspase-3 (M-Fv-Casp 3). In this strategy, a caspase-3 precursor protein is fused with a protein that serves as a chemical binding domain. When a chemical inducer is present, it stimulates formation of dimers of the precursor protein to form active caspase-3 ( Figure 3A ). This strategy can avoid the potential multiple effects of apoptosis inducers. In C2C12 myoblasts, being transfected with M-Fv-Casp 3 did not affect ROCK1 activity. However, the chemical inducer, AP20187, rapidly activated caspase-3, which cleaved ROCK1, producing the activated, 130-kD form of ROCK1 ( Figure 3B ). As expected, increased cleavage of ROCK1 raised ROCK1 kinase activity ( Figure 3C ), suggesting that ROCK1 activation in muscles of mice with CKD is mediated at least in part by caspase-3.
Activated ROCK1 Stimulates PTEN to Diminishing Akt Activity
To ascertain if ROCK1 stimulates PTEN activity, we studied C2C12 myoblasts transfected with M-FvCasp 3 to activate ROCK1. When the inducer, AP20187, was added, PTEN activity increased causing Akt activity to decrease ( Figure 4 , A and B). To examine whether ROCK1 mediated the activation of PTEN, we pretreated C2C12 cells with a ROCK1 inhibitor (100 µg fasudil/ml), followed by activation of caspase-3 by adding AP20187. As shown in Figure 4C , fasudil diminished the activation of PTEN resulting in an increase in Akt activity ( Figure 4D ). Therefore, in skeletal muscle cells, activated caspase-3 may stimulate a pathway from ROCK1 to an increase in PTEN activity that suppresses Akt activity.
CKD Suppresses PI3K Activity but Stimulates PTEN Activity in Muscle
It is well known that CKD causes insulin and IGF-1 resistance resulting in a decrease of Akt activity and a loss of muscle proteins.
The latter occurs because low Akt activity stimulates expression of musclespecific, ubiquitin E3 ligases (MuRF-1 and Atrogin-1/MAFbx), which activate muscle proteolysis in the UPS. What factors reduce the activity of Akt in muscle? One possibility is that suppressed IRS-1-associated PI3K activity lowers the activity of Akt. To evaluate this possibility, we compared the level of IRS-1-associated PI3K activity with that of Akt activity. In response to CKD, we found suppression of both IRS-1-associated PI3K and Akt activities ( Figure 5, A and B) . However, Akt activity was reduced by >70% versus controls and hence to a greater degree than the loss of IRS-1-associated PI3K activity (39% versus control) ( Figure 5C ). This result suggests that other mediators are synergistically suppressing Akt activity in muscles of mice with CKD. To evaluate this possibility, we measured the activity of the PTEN because it functions as a negative regulator of PI3K/Akt signaling.
In mice with CKD, there was a 2.3-fold increase in PTEN activity in muscles ( Figure 5D ). Notably, the decrease was not caused by upregulation of PTEN expression because quantitative RT-PCR and western blotting revealed that both mRNA and protein levels of PTEN in muscles of mice with CKD were not significantly different from the values present in muscles of control mice ( Figure 5 , E and F). We conclude that diminished Akt activity in muscles of mice with CKD occurred because PTEN phosphatase activity increased.
Activation of Caspase-3 in Muscle Cells Forms a Negative Feedback Loop that Causes Muscle Protein Wasting
Because low Akt activity can induce apoptosis by activating caspase-3, we examined whether activation of ROCK1 can in turn stimulate caspase-3 activity. C2C12 myoblasts were cotransfected with two constructs. The first was an expression vector encoding constitutively activated ROCK1 (caROCK1). A second plasmid, the caspase-3 sensor, encodes an enhanced yellow fluorescent protein (EYFP) fusion protein, which translocates to the nucleus when caspase-3 is activated ( Figure 6A ). The expression of caROCK1 resulted in a 3.2-fold increase in caspase-3 activity versus the results obtained by the expression 26 27 , , 1 5 28 , 22 29 30 31 of the control vector ( Figure 6B ), indicating constitutively active ROCK1 stimulates caspase-3 activity in C2C12 myoblasts. Caspase-3 activation was accompanied by an increase in PTEN activity but a decrease in Akt activity versus the control results ( Figure 6 , C and D). Taken together, the results demonstrate that caspase-3 activates ROCK1, which raises PTEN activity, resulting in suppression of Akt. Therefore, these responses form a negative feedback loop that may contribute to loss of muscle proteins.
ROCK1 Knockout or Muscle-Specific PTEN Knockout Prevent CKD-Induced Muscle Wasting
To determine if the negative feedback loop is active in vivo, we studied mice with whole-body knockout (KO) of ROCK1 or with muscle-specific KO of PTEN. ROCK1 KO (ROCK1 ) mice have been characterized and grow normally. Values of BUN and serum creatinine levels in sham-operated, pair-fed ROCK1 or ROCK1 mice with CKD confirmed the presence of renal insufficiency (Table 1 ). In sham-operated, pair-fed, ROCK1 mice, the frequency distribution of the cross-sectional areas of myofibers (CSA) in the tibialis anterior (TA) muscles did not differ from results in the TA muscles of ROCK1 mice ( Figure 7A ). However, the myofiber sizes (CSA) distribution in the TA muscles of ROCK1 mice with CKD was shifted to the right compared with results from pair-fed ROCK1 mice with CKD ( Figure 7B ). The increase in muscle mass of ROCK1 mice with CKD was associated with greater contractile strength of the extensor digitorum longus (EDL) muscles from ROCK1 mice with CKD ( Figure 7C ). To uncover why muscle mass increased in ROCK1 mice we measured protein degradation: there was no difference in the rates of muscle proteolysis in ROCK1 and ROCK1 mice. However, protein degradation in muscles of ROCK1 mice with CKD was significantly lower than that in muscles of ROCK1 mice with CKD ( Figure 7D ). We also found evidence that the UPS was activated because the mRNA of MuRF-1 and Atrogin-1/MAFbx was significantly reduced in muscles of ROCK1 mice with CKD versus ROCK1 mice with CKD ( Figure 7E ). Next, we examined Akt activity in muscles of mice with CKD. As shown in Figure 7F , Akt activity was higher in muscles of ROCK1 mice despite the presence of CKD. The mechanism for the improvement in Akt activity is that PTEN activity in muscle of ROCK1 mice with CKD was reduced ( Figure 7G ). In CKD, therefore, activated ROCK1 raises PTEN activity to suppress Akt in muscles; however, but in ROCK1 mice muscle protein losses caused by CKD were suppressed.
To examine how PTEN activity in muscles of mice with CKD affects protein losses, we studied mice with muscle-specific phosphatase and tensin homolog knockout (MPKO). The generation and characteristics of the MPKO mice have been reported previously. In control mice (lox/lox, Cre-), the frequency distribution of myofiber sizes (CSA) in TA muscles was not statistically different from muscles of MPKO (lox/lox, Cre+) mice ( Figure 8A ). However, when CKD was present, the frequency distribution of CSA myofibers in muscles of MPKO mice was shifted to the right versus results in the control (lox/lox, Cre-) mice ( Figure 8B ). These results indicate that PTEN deletion in muscle blocks the protein losses even in the presence of CKD.
An explanation for this finding is that protein degradation in muscles of MPKO mice with CKD was depressed when compared with muscles of the control (lox/lox, Cre-) mice with CKD ( Figure 8C ). Reduced muscle proteolysis in MPKO mice with CKD involves suppression of the mRNA of both Atrogin-1/MAFbx and MuRF-1 ( Figure 8D ). The decrease in the mRNA can be attributed to an increase in Akt activity, even in mice with CKD ( Figure 8E ). In fact, higher levels of Akt activity were associated with significant decreases in the activities of both caspase-3 and ROCK1 ( Figure 8F ). With the improvements in muscle protein metabolism, contractile strength also increases in the EDL muscles from MPKO mice with CKD ( Figure 8G ). Therefore, an increase in Akt activity in muscles of MPKO mice will suppress the activation of caspase-3 resulting in reduced ROCK1 activation and interruption of the Figure 9 , the decrease in ROCK1 activity prevents muscle wasting in mice with CKD.
Discussion
In cultured C2C12 muscle cells and mouse muscles we have uncovered a novel pathway that begins with activation of caspase-3, which stimulates ROCK1 activity, and is followed by an increase in PTEN phosphatase activity. The latter suppresses Akt activity and thereby accelerates muscle protein catabolism. In cultured C2C12 muscle cells, we used a novel strategy to activate caspase-3 to cleave and activate ROCK1 (Figure 3 ). An increase in ROCK1 activity stimulated PTEN activity and suppressed Akt activity ( Figure 9) . A decrease in Akt activity is a documented stimulus of caspase-3 activity producing a negative feedback loop. We also demonstrated that disrupting this pathway in mouse muscles restored Akt activity and prevented loss of muscle protein. Specifically, when we inhibited ROCK1 or PTEN genetically in mice, the activity of Akt in muscles increased to suppress the expressions of Atrogin-1/MAFbx and MuRF-1. These events resulted in reduced muscle proteolysis. The increase in muscle mass also improved muscle contractile strength (Figures 7 and 8) . Therefore, the negative feedback loop amplifies CKDinduced muscle proteolysis. It is tempting to speculate that similar events may be active in other catabolic conditions associated with insulin resistance and caspase-3 activation. If the negative feedback loop persists, a persistent activation of caspase-3 as could occur with the development of inflammation or worsening of CKD would lead to ongoing activation of muscle protein wasting. However, if inflammation is corrected or dialysis is instituted to remove toxins or exercise is undertaken to raise IGF-1 responses in muscle, caspase-3 activity would decrease and PTEN would be reduced causing a rise in Akt activity. The latter reduces activity of the UPS and promotes muscle growth.
In disorders associated with inflammation, caspase-3 frequently causes apoptosis in epithelial or endothelial cells. In skeletal muscles, however, we found that caspase-3 activation does not cause apoptosis. Instead, caspase-3 remained in the cytoplasm and did not enter the nuclei of myofibers from patients or mice with CKD ( Figure 2) . We confirmed the absence of apoptosis when we found a negative TUNEL assay. In summary, in CKD-induced muscle wasting, caspase-3 activation in muscle fibers stimulates an increase in proteolysis rather than apoptosis/cell death.
How does activated caspase-3 affect muscle wasting? It interacts with the UPS in two ways: first, in response to CKD or diabetes, activated caspase-3 cleaves myofibrillar proteins to produce substrates for the UPS. Second, activated caspase-3 cleaves specific subunits of the 19S particle in the 26S proteasome leading to increased proteolytic activity of the 26S proteasome. The present results uncover another influence of caspase-3 on muscle wasting: caspase-3 stimulates ROCK1 activity, which activates PTEN, resulting in suppressed Akt activity. Low Akt actvity in turn stimulates Atrogin-1 and MuRF-1 expressions leading to muscle wasting. Therefore, caspase-3 activation initiates a coordinated program of muscle proteolysis and atrophy. ROCK1 activity is regulated by small G proteins, such as RhoA, to exert detrimental effects in pathophysiologic conditions, including obesity, cardiovascular diseases, renal fibrosis, and diabetes. Recently, ROCK1 in mouse models of diabetic nephropathy has been identified as a mechanism causing mitochondrial fission and apoptosis in endothelial cells and podocytes. There are other reports that ROCK1 triggered death-inducing signals in many cells but not in skeletal muscles. The demonstration that ROCK1 is activated by caspase-3 is relevant because it elucidates an essential role for ROCK1 in facilitating CKD-induced muscle proteolysis. It is tempting to speculate that inhibition of ROCK1 could improve muscle protein metabolism in patients with CKD. Other mechanisms could adversely affect muscle atrophy, including mitochondrial dysfunction. This is suggested because ROCK1 stimulates mitochondrial fragmentation, a process that can significantly contribute to muscle wasting. Alternatively, CKD-associated muscle protein loss can be initiated by inflammation that stimulates caspase-3, which is associated with the development of CKD-induced insulin resistance.
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insulin signaling by interfering with the metabolism of IRS-1-PI3K and Akt, or they can stimulate NFkB or Stat3 transcription eventually, increase the expression of genes involved in programmed atrophy". Stimulating and eventually, increase the expression of genes involved in programmed atrophy. By uncovering that CKD-associated ROCK1 activation initiates a negative feedback loop to suppress Akt, we present evidence for a new pathway causing muscle wasting.
Our goal in creating models of uremia has been to study the genesis and consequences of abnormal metabolic responses in CKD. Consequently, the CKD model studied here should have some similarities to characteristic abnormalities present in patients with advanced CKD. Because mice and rats rapidly excrete acid and are resistant to the accumulation of waste products, we increased the precursors of acid/waste products, namely high dietary protein. This strategy has been in use since the 1930s, and the model of CKD we study in mice develops metabolic acidosis (serum HCO3=16 mM) with a reasonably stable BUN and serum creatinine.
We recognize that feeding a high protein diet to the rodent model of CKD could influence changes in muscle protein metabolism. Therefore, an interaction resulting from the high protein diet could influence the results of our studies.
In summary, we have identified that caspase-3 activates ROCK1 to initiate a negative feedback loop contributing to CKD-induced muscle protein losses. Inhibition or deletion of ROCK1 or of PTEN aborts this negative feedback loop. These observations could suggest therapeutic strategies inhibiting ROCK1. Alternatively, inhibitors of caspase-3 or PTEN could be developed, but they would require more extensive evaluations.
Concise Methods Animal Models and Muscle Protein Degradation Measurement
Mice were housed with 12-hour light-dark cycles, and all animal procedures were approved by the Baylor College of Medicine Institutional Animal Care and Use Committee. Characteristics of the ROCK1 mice have been described previously. MPKO mice were obtained by crossing loxp-flanked PTEN mice (The Jackson Laboratory, Bar Harbor, ME) with MCK-Cre mice (The Jackson Laboratory). Lox/lox plus Cre+ mice were designated as MPKO mice, and lox/lox plus Cre-mice served as controls. Two-stage nephrectomy of MPKO or lox/lox, control, male mice under anesthesia was used to create CKD. Briefly, approximately 75% of the right kidney was removed, and bleeding was stopped by Vetbond tissue adhesive (3M, St. Paul, MN). One week later the left kidney was removed, and the mice were fed a 24% protein diet for 1 week to minimize death from uremia. Subsequently, mice were fed a 40% protein diet (Harlan Teklab, Indianapolis, IN) for 3 weeks. Sham-operated control mice were pair-fed with CKD mice using the same diets. To confirm CKD, aortic blood obtained from anesthetized mice was used to measure BUN and serum creatinine (Cayman Chemical, Ann Arbor, MI). Under anesthesia, TA muscles were collected for histologic analysis, and EDL and soleus muscles were used for protein degradation measurement as previous described. Gastrocnemius muscles were removed and frozen in liquid nitrogen and stored at -80°C until mRNA and protein were measured. Muscle biopsies were obtained from healthy subjects and patients with CKD as previously described.
Muscle Contractile Function Analysis
EDL muscles were dissected and placed in a chamber containing a Krebs-Ringer buffer (pH 7.4) and equilibrated for 10 min at 35-37°C. At a physiologic optimal length, EDL muscles were stimulated by a Grass S48 stimulator (Grass Technologies, Warwick, RI) with a series of functional frequency (10, 30, 40, 60 , 80, 160, 300Hz). The peak isometric force was measured with 3 min between stimulations. The results were normalized with the weights of EDL muscle. 
Muscle Histologic Examination Sand Immunostaining
with an active caspase-3 antibody followed by Alex 488-secondary antibody (Life Technologies, Carlsbad, CA). Myofibers were outlined by staining of dystrophin (Santa Cruz Technology, Santa Cruz, CA), and nuclei were visualized by DAPI or PI. To determine the CSA, we used Image Pro software (Silver Spring, MD) and assessed sizes of 300 myofibers in muscles of each animal. The negative control was normal rabbit lgG instead of the primary antibody. TUNEL assays were performed following the manufacturer's protocol (EMD Millipore, Billerica, MA).
mRNA Preparation and Expression Analysis
Total RNA was extracted using TRIzol (Sigma-Aldrich, St. Louis, MO) and precipitated in isopropanol. cDNA was synthesized using iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA). SYBR Green Realtime quantitative PCR was performed with CFX96 System (Bio-Rad). The primer sequences for mouse Atrogin-1, MuRF-1, and GAPDH have been reported.
Cell Culture and Western Blot Analyses
C2C12 myoblasts were maintained in DMEM with 10% FBS (HyClone, Logan, UT), penicillin (200 units/ml), and streptomycin (50 μg/ml) (Life Technologies). Plasmid DNA was introduced into cells using Invitrogen transfection system (Life Technologies). The inducible, activated caspase-3 (M-Fv-Casp 3) and control plasmids (without the precursor caspase-3 insert, M-Fv-CTL) were obtained from Addgene (Cambridge, MA). caROCK1 and caspase-3 sensor plasmids were kindly provided by Dr. Jiang Chang. For western blotting, lysates of C1C12 cells were prepared in RIPA buffer (20 mM Tris, pH 7.5, 5 mM EDTA, 150 mM NaCl, 1% NP40, 0.5% Na-deoxycholate, 0.025% SDS, 1 mM Na-orthovanadate, 10 mM NaF, 25 µM β-glycerophosphate) containing protease inhibitors (Roche Diagnostics, Indianapolis, IN). Skeletal muscle lysates were prepared from approximately 50 mg of muscle by homogenizing in 0.5 ml RIPA buffer. After centrifugation at 15,000 g for 15 minutes at 4°C, the supernatants were subjected to western blotting as previously described.
ROCK1, PTEN, PI3K, and AKT Activity Assays
To measure total Rho-kinase activity, cultured cells or muscle samples were lysed in RIPA buffer (containing 0,1 mM EGTA, 0,1 M DTT, 10 mM MgCl2) and added to 500 ng of MYPT1 (654-880; EMD Millipore) plus ATP (1mM). The mixtures are incubated for 30 minutes at 30°C before the reaction is stopped by adding 2× Laemmli Sample Buffer (Sigma-Aldrich). The samples are subjected to western blot using an anti-phospho-MYPT1 (Thr-850; EMD Millipore) at 1:500 dilution. GAPDH is used as the loading control. PTEN activity was measured by immunoprecipitating 500 µg of muscle lysate with anti-PTEN antibody (Cell Signaling Technology, Cambridge, MA) overnight, followed by incubation with protein A/G-agarose for 1 hour at 4°C. Precipitates were washed five times, and enzyme activity was determined using PTEN activity ELISA kit (Echelon Biosciences, Salt Lake City, UT). For PI3K kinase activity, the gastrocnemius muscles (approximately 100 mg) were homogenized, and tissue lysate were immunoprecipitated with 4 μg anti-IRS-1 with protein A/G (25 μl) agarose beads (Santa Cruz Biotechnology) for overnight at 4°C. After washing, the beads were resuspended in 50 μl of PI3K reaction buffer containing 15 μg of phosphatidylinositol (Sigma-Aldrich). Reactions were performed as described previously. The assay of Akt activity assay was performed as per the manufacturer's instruction (Cell Signal Technology). Constitutively active ROCK1 (caROCK1) activates caspase-3 and impairs Akt phosphorylation in C2C12 cells. (A) Structural diagram of the caspase-3 sensor, which was used to detect cytosol caspase-3 activation. EYFP was fused with a nuclear export signal (NES) at its N-terminus and a nuclear localization signal (NLS) at the C-terminus. A caspase-3-specific cleavage site was inserted between NES and EYFP. When caspase-3 is activated, it removes NES from EYFP, and the NSL drives EYFP translocation into the nucleus. (B) C2C12 cells were cotransfected with plasmids expressing the caspase-3 sensor or a caROCK1. Cotransfection of galactosidase and the caspase-3 sensor severed as control (CTL). With ROCK1 activation, EYFP was accumulated in the nuclei indicating caspase-3 activation occurred in the cytoplasm. The caspase-3 activity was also evaluated by the percentage of transfected cells exhibiting nuclear EYFP; at least 100 transfected cells were counted in each experiment (*P<0.01, mean±SEM, n=3). Green represents EYFP-fusion protein; red represents propidium iodide stain of nuclei. 
Statistical Analyses
